Biocept's Immuno-Oncology PD-L1 Test

Biocept has launched its first test for use in guiding cancer immunotherapies, a PD-L1 protein expression assay performed on circulating tumor cells. The CLIA-validated test, developed by Biocept scientists in collaboration with Yale University School of Medicine's David Rimm, is intended to be used to detect and monitor PD-L1 protein expression throughout the course of a patient's treatment with newly approved immuno-oncologic drugs.